Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
Or call (215) 966-6061
SOLUTIONS FOR VIROLOGY AND VACCINE DISCOVERY
Enabling the discovery of vaccines and antiviral therapeutics against SARS-CoV-2, Dengue, Zika, and other viruses
The most extensive catalog of Reporter Virus Particles (RVPs)
Reporter Virus Particles (RVPs) are replication-incompetent pseudovirus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation (learn more)
Our extensive catalog of SARS-CoV-2 variants manufactured with rigorous quality control can help your discovery program meet FDA guidances for COVID-19 vaccines and therapeutics†
SARS-CoV-2 and Emergent Variant RVPs
Catalog No. (G/L*) | SARS-CoV-2 / Variant | WHO | Mutations | D614G |
|---|---|---|---|---|
RVP-701 | Wuhan-Hu-1 | ——— | Reference seq (GenBank QHD43416.1) | No |
RVP-702 | D614G B.1, 20A | ——— | D614G | Yes |
RVP-768 | B.1.1.529.1, BA.1 | Omicron | A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F | Yes |
RVP-771 | B.1.1.529.1.1, BA.1.1 | Omicron | A67V, Δ 69-70, T95I, Δ 142-144, Y145D, Δ 211, L212I, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F | Yes |
RVP-770 | B.1.1.529.2, BA.2 | Omicron | T19I, Δ24-26, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K | Yes |
RVP-775 | B.1.1.529.2.12.1, BA.2.12.1 | Omicron | T19I, LPPA24S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, S704L, N764K, D796Y, Q954H, N969K | Yes |
RVP-774 | B.1.1.529.4/5, BA.4/BA.5 | Omicron | T19I, LPPA24S, HV69del, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K | Yes |
RVP-763 | Indian variant B.1.617.2 | Delta | T19R, G142D, del156/157, R158G, L452R, T478K, P681R, D950N | Yes |
RVP-727 | Indian variant B.1.617, RBD mutations only (“double mutant”) | ——— | L452R, E484Q | Yes |
RVP-730
| Indian variant B.1.617.1
| Kappa
| G142D, E154K, L452R, E484Q, P681R, Q1071H
| Yes
|
RVP-765 | DELTA PLUS (Delta + K417N) B.1.617.2.1 | ——— | T19R, G142D, del156-157, R158G, K417N, L452R, T478K, P681R, D950N | Yes |
RVP-767 | Columbia, B.1.621 | Mu | T95I, Y144T, Y145S, ins146N, R346K,E484K, N501Y, P681H | Yes |
RVP-766
| C.37 | Lambda | G75V, T76I, R246N, del247-253, L452Q, F490S, T859N | Yes |
RVP-736
| Brazilian variant P.2
| Zeta
| E484K, V1176F, D614G
| Yes
|
RVP-728
| UK/Nigerian variant B.1.1.318, 20B/484K
| ———
| T95I, ΔY144, E484K, P681H, D796H
| Yes |
RVP-735
| Bengal variant B.1.618
| ———
| ΔY145-H146, E484K, D614G
| Yes |
RVP-706 | UK variant B.1.1.7, 20I/501Y.V1 | Alpha | ΔH69/V70, ΔY144, N501Y, A570D, P681H, T716I, S982A, D1118H | Yes |
RVP-717 | UK variant B.1.1.7 with E484K | ——— | ΔH69/V70, ΔY144, E484K, N501Y, A570D, P681H, T716I, S982A, D1118H | Yes |
RVP-724 | South African variant Δ3
B.1.351, 20H/501Y.V2
| Beta | L18F, D80A, D215G, ΔL242/A243/L244, R246I, K417N, N501Y, E484K, A701V | Yes |
RVP-726 | New York variant
B.1.526, 20C/484K
| Iota | L5F, T95I, D253G, E484K, A701V | Yes |
RVP-708 | Brazilian variant
P.1, 20J/501Y.V3
| Gamma | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, V1176F | Yes |
RVP-723 | Nigerian/European variant
B.1.525, 20A/484K
| Eta | Q52R, ΔH69/V70, ΔY144, Q677H, F888L | Yes |
RVP-713 | Californian variant
B.1.427/B.1.429, 20C/452R
| Epsilon | S13I, W152C, L452R | Yes |
*All RVPs are available with a GFP (G) or luciferase (L) reporter. Please add G/L to the catalog number when ordering to indicate the preferred reporter gene.
Custom SARS-CoV-2 RVP variants and RVPs from our library of 1,200 alanine spike mutants are available upon request. Please contact us for pricing.
†Learn more about accelerating COVID-19 R&D programs in accordance with FDA guidances
More SARS Variant RVPs
Catalog No. (G/L) | SARS-CoV-2 RVPs / Variants | WHO | Mutations | D614G |
|---|---|---|---|---|
RVP-710 | US/Ohio strain, N501Y
20G/501Y
| ——— | N501Y | Yes |
RVP-711 | S477N (Australian/European variant)** | ——— | S477N | Yes |
RVP-712 | COHD15, US/Ohio variant | ——— | Q677H, L938F | Yes |
RVP-718 | Robin* 20G/677H | ——— | Q677H | Yes |
RVP-719 | Pelican* 20G/677P | ——— | Q677P | Yes |
RVP-721 | Quail* 20B/677H | ——— | Q677H, T732S | Yes |
RVP-722 | Mockingbird* 20A/677H | ——— | G142S, E180V, Q677H | Yes |
RVP-709 | E484K | ——— | E484K | Yes |
RVP-703 | N439K | ——— | N439K | No |
RVP-704 | N439K/D614G
20A/439K
| ——— | N439K | Yes |
RVP-705 | Danish mink “cluster 5” | ——— | ΔH69/V70, Y453F, I692V, M1229I | No |
RVP-725 | US variant N679S*** | ——— | N679S | Yes |
RVP-707 | South African variant
B.1.351, 20C/501Y.V2
| ——— | L18F, D80A, D215G, L242H, R246I, K417N, N501Y, E484K, A701V | Yes |
RVP-714 | South African variant Δ2
B.1.351, 20H/501Y.V2
| ——— | L18F, D80A, D215G, ΔL242/A243, R246I, K417N, N501Y, E484K, A701V | Yes |
RVP-801 | SARS-CoV-1 Urbani | ——— | N/A | N/A |
RVP-901 | MERS-CoV HCoV-EMC (GFP only) | ——— | N/A | N/A |
* Described in Hodcroft et al., 2021
** Described in Hodcroft et al., 2020
***Identified in a newborn with high viral load (LoTempio et al., 2021)
Negative Control RVPs
Catalog No. (G/L) | RVP | Strain |
|---|---|---|
RVP-1002 | VSV with MLV core | Indiana |
VSV with MLV RVPs can be used as a neutralization control with our transgenic ACE2 cells.
Cell Lines
Catalog No. | Transgenes | Expression | Clonality | Origin Cell Line |
|---|---|---|---|---|
C-HA102 | hsACE2 | Stable | Monoclonal | HEK 293T |
Influenza A RVPs
Catalog No. | Virus (Subtype) | Strain Information |
|---|---|---|
RVP-1201 | Influenza A (H5N1) | Indonesia/5/05 |
Influenza B RVPs
Catalog No. | Virus (Lineage) | Strain Information |
|---|---|---|
RVP-1301 | Influenza B (Victoria) | Washington/02/2019 |
Additional RVPs
Catalog No. | Virus | Strain |
|---|---|---|
RVP-1101 | Chikungunya Virus
| S27 |
RVP-101
| Dengue Virus 1
| 16007
|
RVP-201
| Dengue Virus 2
| 16681
|
RVP-301 | Dengue Virus 3
| 16562
|
RVP-401
| Dengue Virus 4
| TVP360
|
RVP-601 | Zika Virus | SPH2015 |
Integral Molecular’s RVPs are produced under stringent quality-controlled conditions
With two decades of virology experience, Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials
Frequently Asked Questions
Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery and antibody discovery against viral targets.
RVPs incorporate virus-specific prM/E proteins and are antigenically equivalent to live wildtype viruses. They contain a modified RNA genome so they are safe and replication incompetent.
RVPs are useful for high-throughput infectivity and neutralization assays. They are an efficient alternative to plaque assays.
Luciferase or GFP is used for quantitative read out.
Integral Molecular does not work with any live viruses capable of causing infectious disease. We have developed Reporter Virus Particles (RVPs) to enable scientists to study viral components without the risk of exposure to viruses or the spread of contagious illnesses.
